Understanding how GATA2 affects blood cancers and MonoMAC syndrome
Official title: The role of GATA2 in myeloid malignancies and MonoMAC syndrome
Funded at Indiana University Indianapolis · NIH-10783945 · Data updated 2026-11-12
This study is looking at how changes in the GATA2 gene might influence the development of acute myeloid leukemia and MonoMAC syndrome, with the hope of finding new treatments for people affected by these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $194,688 |
| NIH project number | 1K22CA285837-01 |
| Project ID | NIH-10783945 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with acute myeloid leukemia or those with MonoMAC syndrome, particularly those with known GATA2 mutations.
✕Less likely to help
Patients without acute myeloid leukemia or MonoMAC syndrome, or those without GATA2 mutations, may not benefit from this research.
What this research studies
This research investigates the role of the GATA2 gene in the development of acute myeloid leukemia (AML) and MonoMAC syndrome. By studying mutations in GATA2, which can either suppress or promote cancer, the researchers aim to uncover how these genetic changes affect blood cell formation and function. The project utilizes advanced techniques like single-cell RNA sequencing to analyze gene expression and protein interactions in specially developed mouse models that mimic human conditions. The ultimate goal is to translate these findings into potential therapeutic strategies for patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for patients with acute myeloid leukemia and MonoMAC syndrome.
How similar studies have gone: Previous research has shown promising results in understanding the role of genetic mutations in blood cancers, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Katerndahl, Casey Duncan Saul — Indiana University Indianapolis
- Study coordinator: Katerndahl, Casey Duncan Saul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.